Tengion appoints Diane Jorkasky to board
This article was originally published in Scrip
Clinical-stage biotech Tengion has appointed Dr Diane Jorkasky to its board of directors, as Brenda Gavin steps down after five years' service. Dr Jorkasky recently joined Endo Pharmaceuticals as senior vice-president of clinical development and chief medical officer, and was previously chief development and medical officer at Aileron Therapeutics.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.